Pharmaceutical
ChemLinkedChemicalFoodCosmeticPharmaceuticalJapanAgrochemicalSustainability
News
Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
INDUSTRY
New Drug COVID-19
China's First Homegrown COVID-19 Pill, Azvudine, is Priced at 270 Yuan Per Bottle China's first domestic oral drugs for COVID-19 treatment, Genuine Biotech's Azuvidine Tablets, is priced at no more than 300 yuan for each bottle, which contains 35 tablets (1mg/tablet). The recommended dosage is 5 mg (five 1mg tablets) per day for a course no longer than 14 days. Thus, a course of Azvudine costs no more than 600 yuan.
Aug 12, 2022
INDUSTRY
Volume-based Procurement Diabetes
How China's Volume-based Procurements (VBPs) Impact Diabetes Medicine Market A total of 27 diabetes drugs, including Empagliflozin, Canagliflozin, and Glipizide, have entered China's national volume-based procurements (VBPs).
Aug 11, 2022
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Drug Registration New Drug COVID-19
Monthly Report: New Drug Approvals in China | July 2022 In July 2022, China NMPA approved 10 new drugs, including 8 chemical drugs and 2 biological products. Among the drugs, Genuine Biotech's Azvudine Tablets is the first homegrown oral drug to get NMPA’s approval for COVID-19 treatment.
Aug 05, 2022
INDUSTRY
Generic Drug OTC Drug API
China's Pharmaceutical Industry Expected to Be the World's Largest in Less Than 10 Years As of 2021, China holds 12% of the global pharmaceutical market, following the United States, responsible for 40% of the total revenue worldwide. Chinese pharma market is reported to have generated 708.75 billion yuan in 2021, while Chinese domestic pharma companies amassed 502 billion USD (3.37 trillion RMB) in revenue.
Jul 28, 2022
INDUSTRY
Marketing Approval Drug Registration COVID-19
China Approves First Domestic Oral Drug for COVID-19 On July 25, China NMPA granted conditional approval to Chinese domestic company Genuine Biotech’s Azvudine Tablets for treating COVID-19 pneumonia.
Jul 28, 2022
INDUSTRY
Marketing Approval Generic Drug Drug Registration
Top 12 Generic Drug Approval Winners in China | H1 2022 In H1 2022, China NMPA approved 210 domestically-manufactured generic drugs for marketing authorization. Yangtze River Pharmaceutical is the biggest winner, owning 14 approved generic drugs.
Jul 14, 2022
INDUSTRY
Marketing Approval Priority Review Innovative Drug Generic Drug New Drug
Monthly Report: New Drug Approvals in China | June 2022 In June 2022, China NMPA approved 25 new drugs, including 17 chemical drugs and 8 biological products.
Jul 08, 2022
INDUSTRY
Law & Regulation Reference Listed Drug (RLD) Marketing Approval Bioequivalence (BE) Drug Registration
CPhI & BaiPharm Event: Generic Drug Application Procedures in China On June 22, BaiPharm is going to co-organize a webinar with CPhI China on the topic of Generic Drug Application Procedures in China.
Jun 21, 2022
INDUSTRY
MAH Marketing Approval Innovative Drug Drug Registration New Drug
Monthly Report: New Drug Approvals in China | May 2022 In May 2022, China NMPA approved 12 new drugs, including 10 chemical drugs and 2 biological products.
Jun 07, 2022
INDUSTRY
MAH Marketing Approval Priority Review Innovative Drug Generic Drug Biological Product Cancer Drug Registration New Drug
Monthly Report: New Drug Approvals in China | April 2022 In April 2022, China NMPA approved 23 new drugs, including 20 chemical drugs and 3 biological products.
May 12, 2022
Pre 1... 45678 ...9 Next
Most Popular